DUBLIN–(BUSINESS WIRE)–The “Global Respiratory Inhaler Devices Market (2020-2025) by Product, Technology, End-User, Disease Indication and Geography and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
In 2020, global revenue generated by respiratory inhaler devices stood at USD 33 billion and is expected to reach USD 40 billion by 2025, growing at a CAGR of 6.9%.
Respiratory inhaler devices are medical devices that assist a patient with respiratory issues like asthma, COPD, and other respiratory disorder. Factors such as increasing air pollution, industrialization, high smoking habits amongst the general population, have led to several respiratory diseases such as asthma and COPD (Chronic Obstructive Pulmonary Disease) across the world. Respiratory disorders have always been a huge challenge for drug manufacturers and medical practitioners. Millions of people suffer from lung cancer in the U.S. As per the WHO data, more than 350 million people in the world are affected by asthma and more than 270 million people are affected by COPD by 2020. Consistent efforts have been made to control and prevent these disorders that affect the majority of the patients.
The growth of the market is attributed to higher demand in the near future due to the increasing number of patients with respiratory diseases. The immune systems of children and older adults are comparatively more prone to chronic respiratory diseases. Developing countries can expect more rise in respiratory diseases due to poverty further worsening the risk factors such as indoor air pollution and tobacco consumption. They add up to the increasing environmental pollution leading to a rise in the number of respiratory diseases.
The market growth is hindered due to technical issues in the inhaler design, lack of effective drugs for a few typical respiratory disorders, high cost associated with the product, side effects, and complications. (Read more…)
Market Dynamics
Drivers
- Widespread Rise in Chronic Respiratory Disease
- Higher Usage of Combination Therapy
- Increasing Requirement for Rescue Medication
- Advancement in Technology
Restraints
- Lack of Single, Effective Device for Every Respiratory Disorder
- Side Effects and Complications During Inhalation
- High Price
- Non-Standardized Dosage
Opportunities
- Advanced Products
- Increasing Requirement in Developing Countries
Why buy this report?
- The report offers a comprehensive evaluation of the Global Respiratory Inhaler Devices Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains a competitive analysis using IGR Competitive Quadrant, a Proprietary competitive positioning tool.
Companies Mentioned
- Baxter International
- Allied Healthcare Products Inc.
- Philips Healthcare
- Propeller Health
- Boehringer Ingelheim GmbH
- Chiesi Pharmaceuticals
- Beximco Pharmaceuticals Ltd.
- Teva Pharmaceutical Industries Ltd.
- OMRON Healthcare
- Smith Medicals
- GlaxoSmithKline Plc.
- Adherium limited
- PARI Medical Holding
- AstraZeneca
- Novartis AG
- 3M Health Care
- Aldo-Union S.A.
- Laboratorio Pablo Cassara S.r.l.
- Lupin Limited
- Merck & Company, Inc.
- Cipla Ltd
For more information about this report visit https://www.researchandmarkets.com/r/3r6bp5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900